In another study, the reduction of AKT signaling has been claimed to explain the lethal synergism of melanoma and thyroid carcinoma cotreatment with BRAF and CK2 inhibitors [89], but, in this case, PTEN was unchanged in cells treated with the CK2 inhibitor, suggesting a different level for the action of CK2 on this pathways. The gene discussed is BRAF; the disease is thyroid gland carcinoma.